Current role of diethylstilbestrol in the management of advanced prostate cancer

BJU International

Volumn 110, Issue 11 C, 2012, Pages

  Bosset, Pierre Olivier ^a   Albiges, Laurence ^c   Seisen, Thomas ^a   De La Motte Rouge, Thibault ^b   Phé, Véronique ^a   Bitker, Marc Olivier ^a   Rouprêt, Morgan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre de Lutte Contre le Cancer (CLCC)   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Androgen deprivation therapy; Diethylstilbestrol; Hormone resistant prostate cancer; Low molecular weight heparin; Progression; PSA

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOCETAXEL; GONADORELIN DERIVATIVE; GOSERELIN; ESTROGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASTRATION RESISTANT PROSTATE CANCER; CELL FUNCTION; CLINICAL PRACTICE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; GYNECOMASTIA; HORMONE RELEASE; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; NEGATIVE FEEDBACK; ORCHIECTOMY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THROMBOEMBOLISM; MALE; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

DIETHYLSTILBESTROL; ESTROGENS, NON-STEROIDAL; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84873265898     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11206.x     Document Type: Review

References (30)

1. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001 ; 58 : 108-13
2. Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973 ; 32 : 1126-30
3. Shamash J, Stebbing J, Sweeney C et al. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrateresistant prostate cancer. Cancer 2010 ; 116 : 3595-602
4. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer 2009 ; 7 : E71-6
5. Robinson MR, Thomas BS. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. B MJ 1971 ; 4 : 391-4
6. Geisler J, Haynes B, Anker G et al. Treatment with high-dose estrogen (diethylstilbestrol) signifi cantly decreases plasma estrogen and androgen levels but does not infl uence in vivo aromatization in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 2005 ; 96 : 415-22 (Pubitemid 41384142)
7. Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 2010 ; 70 : 1307-12
8. Wang H, Li J, Gao Y et al. Xenooestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl 2010 ; 12 : 535-47
9. The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967 ; 124 : 1011-7
10. Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffi n PP, Young HH. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitarygonadal axis. Urology 1976 ; 7 : 148-55
11. Kent JR, Bischoff AJ, Arduino LJ et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 1973 ; 109 : 858-60
12. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998 ; 52 : 257-60 (Pubitemid 28357829)
13. Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol 2011 ; doi:10.1016/j.urolonc. 2010.12.004
14. Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in ' hormonerefractory'prostate cancer. A nn Oncol 2000 ; 11 : 177-81 (Pubitemid 30148731)
15. Rosenbaum E, Carducci MA. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. E xpert Opin Pharmacother 2003 ; 4 : 875-87 (Pubitemid 36722479)
16. Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: fl utamide versus diethylstilbestrol. J Clin Oncol 1996 ; 14 : 2250-7 (Pubitemid 26264875)
17. Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999 ; 1 61 : 169-72 (Pubitemid 29422313)
18. Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. BJU Int 1996 ; 78 : 921-8 (Pubitemid 27407797)
19. Serrate C, Loriot Y, De La Motte Rouge T et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009 ; 20 : 965
20. Attard G, Reid AHM, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confi rms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008 ; 2 6 : 4563-71
21. Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011 ; 185 : 787-94
22. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 ; 324 : 787-90
23. Huggins CB. Propositions in hormonal treatment of advanced cancers. JAMA 1965 ; 192 : 1141-5
24. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The relationship between cardiovascular complications of estrogen therapy and fi brinolysis in patients with prostatic cancer. Prostate 1992 ; 21 : 35-9
25. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986 ; 135 : 303-7 (Pubitemid 16131365)
26. Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The fi nal analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995 ; 28 : 273-83
27. Waymont B, Lynch TH, Dunn JA et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. BJU Int 1992 ; 69 : 614-20
28. Manikandan R, Srirangam SJ, Pearson E, Brown SCW, O'Reilly P, Collins GN. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005 ; 75 : 217-21 (Pubitemid 41433869)
29. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J-F, Suissa S. Androgendeprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 2011 ; 60 : 1244-50
30. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003 ; 61 : 14-24 (Pubitemid 36349538)